1. Home
  2. PPCB vs ACCS Comparison

PPCB vs ACCS Comparison

Compare PPCB & ACCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PPCB
  • ACCS
  • Stock Information
  • Founded
  • PPCB 2007
  • ACCS 1988
  • Country
  • PPCB Australia
  • ACCS United States
  • Employees
  • PPCB N/A
  • ACCS N/A
  • Industry
  • PPCB
  • ACCS Publishing
  • Sector
  • PPCB
  • ACCS Consumer Discretionary
  • Exchange
  • PPCB Nasdaq
  • ACCS Nasdaq
  • Market Cap
  • PPCB 39.1M
  • ACCS 42.6M
  • IPO Year
  • PPCB N/A
  • ACCS N/A
  • Fundamental
  • Price
  • PPCB $1.91
  • ACCS $10.46
  • Analyst Decision
  • PPCB
  • ACCS Strong Buy
  • Analyst Count
  • PPCB 0
  • ACCS 1
  • Target Price
  • PPCB N/A
  • ACCS $14.00
  • AVG Volume (30 Days)
  • PPCB 316.9K
  • ACCS 5.5K
  • Earning Date
  • PPCB 09-30-2025
  • ACCS 11-06-2025
  • Dividend Yield
  • PPCB N/A
  • ACCS N/A
  • EPS Growth
  • PPCB N/A
  • ACCS N/A
  • EPS
  • PPCB N/A
  • ACCS N/A
  • Revenue
  • PPCB N/A
  • ACCS $22,562,000.00
  • Revenue This Year
  • PPCB N/A
  • ACCS $0.03
  • Revenue Next Year
  • PPCB N/A
  • ACCS $11.45
  • P/E Ratio
  • PPCB N/A
  • ACCS N/A
  • Revenue Growth
  • PPCB N/A
  • ACCS 26.44
  • 52 Week Low
  • PPCB $1.25
  • ACCS $7.79
  • 52 Week High
  • PPCB $145.46
  • ACCS $13.35
  • Technical
  • Relative Strength Index (RSI)
  • PPCB N/A
  • ACCS 42.43
  • Support Level
  • PPCB N/A
  • ACCS $10.49
  • Resistance Level
  • PPCB N/A
  • ACCS $10.90
  • Average True Range (ATR)
  • PPCB 0.00
  • ACCS 0.50
  • MACD
  • PPCB 0.00
  • ACCS 0.01
  • Stochastic Oscillator
  • PPCB 0.00
  • ACCS 62.13

About PPCB Propanc Biopharma Inc.

Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.

About ACCS ACCESS Newswire Inc.

ACCESS Newswire Inc is a Public Relations (PR) and Investor Relations (IR) solutions provider. The group focuses on innovation, customer service, and value-driven offerings, ACCESS Newswire empowers brands.

Share on Social Networks: